<SEC-DOCUMENT>0001209191-17-053713.txt : 20170922
<SEC-HEADER>0001209191-17-053713.hdr.sgml : 20170922
<ACCEPTANCE-DATETIME>20170922163412
ACCESSION NUMBER:		0001209191-17-053713
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170920
FILED AS OF DATE:		20170922
DATE AS OF CHANGE:		20170922

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			van Deventer Sander
		CENTRAL INDEX KEY:			0001543084

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		171097937

	MAIL ADDRESS:	
		STREET 1:		POSTBUS 5187
		CITY:			NAARDEN
		STATE:			P7
		ZIP:			1410 AD

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	BUSINESS ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-09-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001590560</issuerCik>
        <issuerName>uniQure N.V.</issuerName>
        <issuerTradingSymbol>QURE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001543084</rptOwnerCik>
            <rptOwnerName>van Deventer Sander</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O UNIQURE N.V.</rptOwnerStreet1>
            <rptOwnerStreet2>PAASHEUVELWEG 25A</rptOwnerStreet2>
            <rptOwnerCity>AMSTERDAM</rptOwnerCity>
            <rptOwnerState>P7</rptOwnerState>
            <rptOwnerZipCode>P7 1005 BP</rptOwnerZipCode>
            <rptOwnerStateDescription>NETHERLANDS</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Scientific Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.49</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2017-09-20</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>150000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-09-20</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>150000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>150000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The first tranche of 25% vests on September 20, 2018, with the remainder vesting in tranches of 6.25% each quarter thereafter over three years.</footnote>
    </footnotes>

    <remarks>Exhibit List: Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Christian Klemt, Attorney-in-Fact</signatureName>
        <signatureDate>2017-09-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.4_745057
<SEQUENCE>2
<FILENAME>poa.txt
<DESCRIPTION>POA DOCUMENT
<TEXT>
POWER OF ATTORNEY

I hereby constitute and appoint each of Matthijs van Blokland and Christian
Klemt, signing singly, my true and lawful attorney-in-fact to:

(1)	execute on my behalf any Form 3-Initial Statement of Beneficial Ownership of
Securities, Form 4-Statement of Changes of Beneficial Ownership of Securities,
or Form 5-Annual Statement of Beneficial Ownership of Securities, including any
amendments, supplements or exhibits thereto (each, a "Section 16 Report"), which
I am required to file in my capacity as an officer, director or owner of greater
than 10% of the outstanding shares of uniQure N.V. (the "Company") in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Act") and the rules thereunder;

(2)	do and perform any and all acts for and on my behalf that may be necessary
or desirable to complete and execute any Section 16 Report and timely file such
report with the United States Securities and Exchange Commission and any stock
exchange or similar authority;

(3)	seek or obtain, as my representative and on my behalf, information on
transactions in the Company's securities from any third party, including
brokers, employee benefit plan administrators and trustees, and I hereby
authorize any such third party to release any such information to each of my
attorneys-in-fact appointed by this Power of Attorney; and

(4)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be to my benefit,
in my best interest, or that I am legally required to do, it being understood
that the documents executed by such attorney-in-fact on my behalf pursuant to
this Power of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such attorney-in-fact's
discretion.

I hereby grant to each attorney-in-fact hereunder full power and authority to do
and perform any and every act and thing whatsoever necessary or desirable to be
done in the exercise of any of the rights and powers herein granted, as fully to
all intents and purposes as I might or could do if personally present, with full
power of substitution or revocation, hereby ratifying and confirming all that
such attorney-in-fact, or such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this Power of Attorney and
the rights and powers herein granted.

I acknowledge that this Power of Attorney does not relieve me of my
responsibilities to comply with Section 16 of the Act and the attorneys-in-fact,
in serving in such capacity at my request, are not assuming, nor is the Company
assuming, any of my responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until I am no
longer required to file Section 16 Reports with respect to my holdings of and
transactions in Company securities, unless I earlier revoke it in a signed
writing delivered to the attorneys-in-fact.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of
this 21st day of September, 2017.

By:  /s/ Sander van Deventer

Print Name: Sander van Deventer

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>3
<FILENAME>attachment1.htm
<DESCRIPTION>EX-24 DOCUMENT
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY>
<PRE>



</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
